Calciphylaxis: Natural history, risk factor analysis, and outcome

Journal of the American Academy of Dermatology

Volumn 56, Issue 4, 2007, Pages 569-579

  Weenig, Roger H ^a   Sewell, Lindsay D ^a   Davis, Mark D P ^a   McCarthy, James T ^b   Pittelkow, Mark R ^a  

^a Department of Dermatology ^*  (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALUMINUM; CALCIUM; CALCIUM PHOSPHATE; CORTICOSTEROID; ERYTHROPOIETIN; ESTROGEN; IRON; IRON DEXTRAN; PHOSPHATE BINDING AGENT; VITAMIN D; VITAMIN D DERIVATIVE; WARFARIN;

ADULT; AGED; ALUMINUM BLOOD LEVEL; ARTICLE; CALCINOSIS; CONTROLLED STUDY; DEBRIDEMENT; DISEASE COURSE; FEMALE; HEMODIALYSIS PATIENT; HUMAN; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; OBESITY; OUTCOME ASSESSMENT; PARATHYROIDECTOMY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CALCIPHYLAXIS; CASE-CONTROL STUDIES; CAUSE OF DEATH; COMBINED MODALITY THERAPY; DEBRIDEMENT; FACTOR ANALYSIS, STATISTICAL; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; LOGISTIC MODELS; MALE; MIDDLE AGED; PARATHYROIDECTOMY; PROPORTIONAL HAZARDS MODELS; RARE DISEASES; REFERENCE VALUES; RENAL DIALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; SURVIVAL ANALYSIS;

EID: 33947169998     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2006.08.065     Document Type: Article

References (24)

1. Kang A.S., McCarthy J.T., Rowland C., Farley D.R., and van Heerden J.A. Is calciphylaxis best treated surgically or medically?. Surgery 128 (2000) 967-971
2. Selye H., Gentile G., and Prioreschi P. Cutaneous molt induced by calciphylaxis in the rat. Science 134 (1961) 1876-1877
3. Bleyer A.J., White W.L., and Choi M.J. Calcific small vessel ischemic disease (calciphylaxis) in dialysis patients. Int J Artif Organs 23 (2000) 351-355
4. Anderson D.C., Stewart W.K., and Piercy D.M. Calcifying panniculitis with fat and skin necrosis in a case of uraemia with autonomous hyperparathyroidism. Lancet 2 (1968) 323-325
5. Dahl P.R., Winkelmann R.K., and Connolly S.M. The vascular calcification-cutaneous necrosis syndrome. J Am Acad Dermatol 33 (1995) 53-58
6. Janigan D.T., Hirsch D.J., Klassen G.A., and MacDonald A.S. Calcified subcutaneous arterioles with infarcts of the subcutis and skin ("calciphylaxis") in chronic renal failure. Am J Kidney Dis 35 (2000) 588-597
7. Coates T., Kirkland G.S., Dymock R.B., Murphy B.F., Brealey J.K., Mathew T.H., et al. Cutaneous necrosis from calcific uremic arteriolopathy. Am J Kidney Dis 32 (1998) 384-391
8. Lopez-Brea M., and Selgas R. [Nanobacteria as a cause of renal diseases and vascular calcifying pathology in renal patients ("endovascular lithiasis").]. Enferm Infecc Microbiol Clin 18 (2000) 491-492 Spanish
9. Torok L., and Kozepessy L. Uraemic gangrene syndrome. Acta Derm Venereol 71 (1991) 455-457
10. Huang L., Xu J., Kumta S.M., and Zheng M.H. Gene expression of glucocorticoid receptor α and β in giant cell tumour of bone: evidence of glucocorticoid-stimulated osteoclastogenesis by stromal-like tumour cells. Mol Cell Endocrinol 181 (2001) 199-206
11. Hofbauer L.C., Gori F., Riggs B.L., Lacey D.L., Dunstan C.R., Spelsberg T.C., et al. Stimulation of osteoprotegerin ligand and inhibition of osteroprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 140 (1999) 4382-4389
12. Coen G., Ballanti P., Balducci A., Calabria S., Fischer M.S., Jankovic L., et al. Serum osteoprotegerin and renal osteodystrophy. Nephrol Dial Transplant 17 (2002) 233-238
13. Ma Y.L., Cain R.L., Halladay D.L., Yang X., Zeng Q., Miles R.R., et al. Catabolic effects of continuous human PTH (1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology 142 (2001) 4047-4054
14. Khoruts A., Stahnke L., McClain C.J., Logan G., and Allen J.I. Circulating tumor necrosis factor, interleukin-1 and interleukin-6 concentrations in chronic alcoholic patients. Hepatology 13 (1991) 267-276
15. Kim W.H., Hong F., Jaruga B., Hu Z., Fan S., Liang T.J., et al. Additive activation of hepatic NF-κB by ethanol and hepatitis B protein X (HBX) or HCV core protein: involvement of TNF-α receptor 1-independent and -dependent mechanisms. FASEB J 15 (2001) 2551-2553
16. Zhang H., and Johnson P. Differential effects of aluminum ion on smooth muscle calpain I and calpain II activities. Int J Biochem 24 (1992) 1773-1778
17. Luo G., Ducy P., McKee M.D., Pinero G.J., Loyer E., Behringer R.R., et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 386 (1997) 78-81
18. Mehta R.L., Scott G., Sloand J.A., and Francis C.W. Skin necrosis associated with acquired protein C deficiency in patients with renal failure and calciphylaxis. Am J Med 88 (1990) 252-257
19. Goldsmith D.J. Calciphylaxis, thrombotic diathesis and defects in coagulation regulation. Nephrol Dial Transplant 12 (1997) 1082-1083
20. Alain J., Poulin Y.P., Cloutier R.A., Gagne E., and Baril J. Calciphylaxis: seven new cases. J Cutan Med Surg 4 (2000) 213-218
21. Wong J.J., Laumann A., and Martinez M. Calciphylaxis and antiphospholipid antibody syndrome. [letter]. J Am Acad Dermatol 42 (2000) 849
22. London G.M., Marty C., Marchais S.J., Guerin A.P., Metivier F., and de Vernejoul M.C. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 15 (2004) 1943-1951
23. London G.M., Guerin A.P., Marchais S.J., Metivier F., Pannier B., and Adda H. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 18 (2003) 1731-1740
24. Price P.A., June H.H., Buckley J.R., and Williamson M.K. Osteoprotegerin inhibits artery calcification induced by warfarin and vitamin D. Arterioscler Thromb Vasc Biol 21 (2001) 1610-1616